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This commentary will discuss the clinical implications of the
advances surrounding the Toll-like receptor (TLR), reviewed
elsewhere in this issue by Opal and Huber [1]. Most human
pathogens are readily killed in vitro by antibiotics. In addition,
our antimicrobial therapy is so successful that it has
provoked highly sophisticated adaptive changes by the
pathogens themselves. Despite widespread use of these
treatments, it has been estimated that there are 750,000
cases of severe sepsis per year in the US, at a cost of
$16.7 billion [2]. When there is progression to septic shock,
mortality remains as high as 50% [2,3]. Indeed, despite over
30 randomised, blinded studies using blocking antibodies
against inflammatory cytokines and their receptors [3],
antibiotics remain the mainstay of treatment. Even recent
successes in countering the derangement in coagulation and
fibrinolysis are not consistent [4].
Critically, the marked variations in the tempo and intensity of
the host response remain largely unexplained. We still do not
know why some patients live and why some die. In
meningococcal sepsis, fatal multi-organ failure can occur
within a matter of hours despite appropriate antibiotic therapy
and supportive care. Once a patient has developed such
derangement of their inflammatory cascades, our efforts in
the intensive care unit are often akin to locking the stable
door after the horse has bolted. It has taken a breakthrough
in our understanding of how more simple organisms defend
themselves to perhaps finally begin to offer the explanation as
to why this might be.
Opal and Huber describe in their review [1] how the
defensive mechanisms of the Drosophila fruit fly, which has
no adaptive immunity, have been conserved to a remarkable
degree in the innate immune response of higher mammals.
The recent interest in innate immunity has been
characterised by new understanding of several key
components. These include antimicrobial polycationic
peptides [5], bactericidal permeability-increasing protein, the
triggering receptor expressed on myeloid cells TREM-1 [6],
and macrophage migration inhibitory factor [7]. It is pattern
recognition receptors on the host–pathogen interface,
however, that represent one of the most exciting
developments. Pattern recognition receptors, including
CD14 [8] and CD11b/CD18 [9], recognise conserved
regions on the invading organism called pattern-associated
molecular patterns.
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Abstract
Severe sepsis continues to lead to critical illness. Few therapeutic options exist other than antibiotic
therapy and general supportive care. Large numbers of patients continue to die as a consequence of
overactivation of the host inflammatory response and the resultant coagulopathy and disregulation of
the normal controls of vasoactive tone. It is now known that a critical part of this host response occurs
at the level of innate defence, without the need for antigen processing or the clonal expansion of cells
targeted against the invading pathogen. This commentary will discuss the therapeutic targets revealed
by our new understanding of the Toll-like receptor. The potential clinical difficulties that may result from
intervention at this pattern-recognition receptor will also be explored.
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Opal and Huber review the recently described biology
surrounding the latest member of the interleukin-1 receptor
superfamily, the human homologue of the Drosophila Toll
receptor, which was first described in Janeway’s laboratory
[10]. It appears that it is members of this TLR group that can
differentiate potential pathogens (including viruses [11]) from
self, using an apparently limited number of pattern
recognition receptors. The rapid progress in our
understanding of the TLR system [1] may soon allow us to
answer some important clinical questions.
First, why can severe sepsis overwhelm a patient so quickly?
Innate immunity operates at a very different tempo to that of
the adaptive response since its effector cells perform their
function without proliferation. For example, TLRs are not
expressed in a clonal way: all such receptors displayed by
cells of a given type, for example dendritic cells [1], have
identical specificities.
Second, why do some patients live and some die? While
the effect of Toll sequence polymorphisms on
susceptibility to infection [12] may be as important as it is
in plants [13], there may be other reasons for this
interindividual variability. In endotoxin tolerance there
appears to be important downregulation of TLR4 [14]. A
failure of this mechanism could produce a devastating
overactivation of inflammatory cascades. In addition,
critical differences in host response could also result from
variations in innate repertoire. The latter hypothesis is
supported by the finding that the TLR system is far more
complex than simply a collection of well-conserved germ-
line receptors. This system is now known to involve soluble
components and complex interaction or co-segregation of
receptors; for example, RP105 and TLR4 heterodimers at
the cell surface [15,16]. These cell-surface activities are
linked to diverse intracellular events involving interrogation
of pathogens at phagasomes by TLR2 [17] and activity of
the intracellular proteins Nod1 and Nod2, which are
structurally related to TLRs [16]. A final layer of complexity
exists with various TLR pathways interacting at the level of
transcription.
The cell surface collaboration between receptors is further
complicated by the different receptor profiles presented by
different host tissues. An important example of this is the
finding that, under certain circumstances, gut epithelial cells
[18] and hepatocytes [19] can both express TLRs. Both are
key sites in the early events of septic shock and other severe
sepsis syndromes like faecal peritonitis. In the latter, a large
number of pattern-associated molecular patterns will flood
the local TLR cell surface array. Indeed, mixed infection
models do appear to produce adverse upregulation of the
host response [20]. Beutler et al. have suggested that, while
the host will tolerate some pattern-associated molecular
profiles, others will trigger overactivation of inflammatory
cascades [21].
Finally, how can we intervene in such crucial early events?
Opal and Huber suggest three broad therapeutic strategies:
the use of soluble TLRs specific for a particular organism;
peptides or antibodies that interfere with extracellular
domains of TLRs; or interference with intracellular events
such as the recruitment of the adapter protein, MyD88. Such
strategies will unfortunately suffer from the relatively late
presentation of patients to the intensive care unit, thought to
be one factor in the failure of most sepsis trials to date. Also,
intervention may neutralise beneficial components of the host
defence. In animal systems in which there has been
successful prevention of lipopolysaccharide responsiveness
with Toll knockout or blocking antibodies, the animals die
from overwhelming bacterial sepsis [1]. Intervention may also
block advantageous tolerance to subsequent fungal, bacterial
or viral triggers.
In reality, progress in critical care derived from understanding
of TLR biology may initially centre on improvements in
established therapies. For example, the timing or mode of
delivery of antimicrobial therapy together with other efforts to
augment host defence [4] may turn out to be crucially
important. The finding that TLR9 is sensitive to bacterial DNA
[22], which is variably released before and after antibiotic
therapy [23], may explain some of the adverse events that
occur on using these agents [24]. The indiscriminate use of
antimicrobials may also critically change the type of lipid A to
which the host is exposed. Some lipid A species are
recognised by TLR4 as an antagonist, while canonical lipid A
from Enterobacteriaceae, a well-known group of noscomial
organisms, would be seen as a TLR4 agonist [16]. Other
more experimental interventions such as early high-volume
haemodiafiltration or plasma exchange, which have a highly
variable ability to remove both toxins and cytokines [25],
could convert a protective downregulation to a harmful
upregulation of host immune response.
In order that we can effectively intervene at the earliest
events in the septic cascade, we may need to identify the
ligands for TLRs, perhaps homologous to those found
recently in Drosophilae [26]. Description of the three-
dimensional crystal structure of these crucial pattern-
recognition receptors may also be required. Only then will we
be able to claim that we have the key to the stable door.
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